T cell disease treatment targeting TAG-72
US12281150B2 · kind B2 · utility
0Cited by
4References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 18, 2019 |
| Grant date | Apr 22, 2025 |
| Priority date | — |
| Expiry date | Apr 5, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/03
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure relates to treatment of T cell diseases, particularly T cell lymphomas (TCLs) including, in particular, cutaneous T cell lymphomas (CTCLs) such as Sezary Syndrome (SS) and mycosis fungoides (MF), by targeting tumor-associated glycoprotein-72 (TAG-72).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.